Moreover, the reduced viability of ER-positive and -negative cancer cell lines treated with FVE through inactivation of the PI3K/Akt/mTOR pathway suggests that FVE may be useful in the treatment of some breast, endometrial and ovarian cancers regardless of ER status. This evidence concerns the gene AKT1 and ovarian carcinoma.